Faculty profile

Carlo DeAngelis

Back to faculty

Assistant ProfessorStatusUniversity of Toronto

Carlo DeAngelis

Assistant Professor

Status

Leslie Dan Faculty of Pharmacy

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
6 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

116

Publications

2,017

Citations

Collaborators

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Uptake of oncology-related biosimilars: a global analysis of usage data.
Journal of the National Cancer Institute · 2026
Implementation and Resource Optimization of an Oral Anticancer Medication Clinical Pharmacy Trainee Program: Operational and Financial Impact at a Tertiary Cancer Centre.
Current oncology (Toronto, Ont.) · 2026 · senior author
2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024

All 116 publications

116 publications.

Uptake of oncology-related biosimilars: a global analysis of usage data.

Ho MKH, Chaudhry S, Chai J, DeAngelis C, Chan KKW, Tadrous M

Journal of the National Cancer Institute20262 citations

DOI: 10.1093/jnci/djaf335 PMID: 41259011

Implementation and Resource Optimization of an Oral Anticancer Medication Clinical Pharmacy Trainee Program: Operational and Financial Impact at a Tertiary Cancer Centre.

Peragine C, Charbonneau F, Singh S, DeAngelis C

Current oncology (Toronto, Ont.)2026Senior author

DOI: 10.3390/curroncol33090523 PMID: 42782870

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients.

Kennedy SKF, Goodall S, Lee SF, DeAngelis C, Jocko A, Charbonneau F, Wang K, Pasetka M, Ko YJ, Wong HCY, Chan AW, Rajeswaran T, Gojsevic M, Chow E, Gralla RJ, Ng TL, Jerzak KJ

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

DOI: 10.1007/s00520-024-08462-x PMID: 38594320

The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study.

Wong G, Wang K, Pasetka M, Zhang L, Lou J, Majeed H, Flores J, Lam E, DeAngelis C

Current oncology (Toronto, Ont.)2022Senior author

DOI: 10.3390/curroncol29030115 PMID: 35323315

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.

Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

DOI: 10.1007/s00520-021-06606-x PMID: 34613472

A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).

Wong G, Zhang L, Majeed H, Razvi Y, DeAngelis C, Lam E, McKenzie E, Wang K, Pasetka M

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2022

DOI: 10.1177/1078155220974085 PMID: 33215563

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature

Ronald Chow, Jørn Herrstedt, Matti Aapro, Leonard Chiu, Henry Lam, Elizabeth Horn Prsic, Michael I. Lock, Carlo DeAngelis, Rudolph M. Navari

Supportive Care in Cancer202138 citationsOpen Access

DOI: 10.1007/s00520-020-05935-7 PMID: 33442782

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients

Ronald Chow, Leonard Chiu, Jørn Herrstedt, Matti Aapro, Michael I. Lock, Carlo DeAngelis, Rudolph M. Navari

Supportive Care in Cancer202113 citations

DOI: 10.1007/s00520-020-05977-x PMID: 33409724

Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?

Leonard Chiu, Ronald Chow, Carlo DeAngelis, Michael I. Lock, Charles B. Simone

Annals of Palliative Medicine20213 citationsOpen Access

DOI: 10.21037/apm-20-1462 PMID: 33440973

Patient-Reported Pain in Patients with Breast Cancer Who Receive Radiotherapy.

Wan BA, Pidduck W, Zhang L, Nolen A, Yee C, Wang K, Chow S, Chan S, Drost L, Soliman H, Leung E, Sousa P, Lewis D, DeAngelis C, Taylor P, Chow E

Pain management nursing : official journal of the American Society of Pain Management Nurses2021

DOI: 10.1016/j.pmn.2020.12.007 PMID: 33485785

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Carlo DeAngelis

Research

Latest papers

Uptake of oncology-related biosimilars: a global analysis of usage data.

Implementation and Resource Optimization of an Oral Anticancer Medication Clinical Pharmacy Trainee Program: Operational and Financial Impact at a Tertiary Cancer Centre.

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients.

The Real-World Experience of the Biosimilar (Grastofil&#xae;) to the Reference Biologic (Neupogen&#xae;) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study.

Olanzapine 5&#xa0;mg vs 10&#xa0;mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.

A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga&#xae;) to the reference biologic (Neulasta&#xae;).

Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients

Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?

Patient-Reported Pain in Patients with Breast Cancer Who Receive Radiotherapy.

Frequent collaborators

Edward Chow

May Tsao

Marko Popovic

Elizabeth Barnes

Carolyn Wilson

Keyue Ding

Hany Soliman

Michael Lock

Ralph Meyer

Hans Chung

Michael Brundage

Joda Kuk

Arjun Sahgal

Sunil Verma

Eric Leung

Andrea Bezjak

Raimond Wong

Rebecca Wong

Shun Wong

Urban Emmenegger

Eileen Rakovitch

George Charames

Janet Ellis

Danny Vesprini

Erin Wong

Hsien-Yeang Seow

Rinku Sutradhar

Justin Lee

Clare Atzema

Kelvin Chan

Hsien Seow

Gunita Mitera

Lori Holden

Nadil Zeiadin

William Chu

Daniela Gallo-Hershberg

Aruz Mesci

Jay Detsky

Kucy Pon

Laura D'Alimonte

The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study.

Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.

A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).